Table 2.
Baseline data of the two groups
| YM (40 cases) | Control treatment (40 cases) | |
|---|---|---|
| Gender | ||
| Male | 8 | 11 |
| Female | 32 | 29 |
| Age (year) | 36.50 (17.00) | 38.00 (24.50) |
| Course of disease (month) | 11.00 (16.25) | 12.50 (18.50) |
| Primary cases (number) | 18 | 18 |
| Recurrent cases (number) | 22 | 22 |
| FT3 (pmol/l) | 18.22 (14.87) | 14.25 (14.88) |
| FT4p (mol/l) | 46.75 (34.95) | 39.34 (27.24) |
| TSHm (IU/L) | 0.004 (0.00) | 0.004 (0.00) |
| TGAb (IU/ML) | 89.90 (370.92) | 89.62 (355.11) |
| TPOAb (IU/ML) | 54.80 (229.20) | 27.80 (250.15) |
| TRAbm (IU/ML) | 12.89 (17.10) | 12.17 (7.43) |
| Symptome score (X̅±sd) | 18.45±2.50 | 18.55±2.05 |